vTv Therapeutics Announces Licensing Agreement with Newsoara Biopharma Co. Ltd. to Rights for vTv’s PDE4 Inhibitor in China and Other Pacific Rim Territories

HIGH POINT, N.C.--()--vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into an exclusive licensing agreement with Newsoara Biopharma Co., Ltd. for rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries covering Thailand, Vietnam, Indonesia, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos, Brunei and South Korea.

Under the terms of the agreement, vTv Therapeutics will receive an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on sales of approved products. Newsoara will develop HPP737 in the covered territories for respiratory and other inflammatory diseases.

HPP737, a selective phosphodiesterase type 4 (PDE4) inhibitor, has shown therapeutic activity in several animal models of inflammation. In phase 1 studies, HPP737 was well tolerated with little or no gastrointestinal distress. Preclinical and clinical data suggest that HPP737 may be able to expand the therapeutic use for this target, which has been limited by the side-effects of currently-available PDE4 inhibitors.

“We are excited to partner with Newsoara, an innovative biotechnology company in China with an outstanding experienced management team, led by Dr. Benny Li, to develop and commercialize our PDE4 program in the licensed Asian countries,” stated Steve Holcombe, chief executive officer of vTv Therapeutics. “This represents our second partnership to introduce potential new therapies into the China market which speaks to the importance of that market.”

“With this partnership, we hope to develop a new treatment for inflammatory diseases, including COPD, which is one of the major health care burdens in China, with over eight percent of the country’s adult population suffering from the disease and limited safe and effective treatment options available,” said Dr. Li, CEO of Newsoara.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and diabetes as well as treatment of inflammatory disorders.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.

Contacts

vTv Therapeutics Inc.
Investor Relations:
Mike Biega, 617-221-9660
IR@vtvtherapeutics.com
or
Media Relations:
Josh Vlasto, 212-572-5969
PR@vtvtherapeutics.com

Contacts

vTv Therapeutics Inc.
Investor Relations:
Mike Biega, 617-221-9660
IR@vtvtherapeutics.com
or
Media Relations:
Josh Vlasto, 212-572-5969
PR@vtvtherapeutics.com